Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We confirmed that FGF23 treatment activates PLCγ in the heart and induces LVH in the absence of membrane α-Klotho.
|
31758962 |
2020 |
Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>α</i>-Klotho deficiency renders the kidney more susceptible to injury and results in cardiovascular calcification and left ventricular hypertrophy in chronic kidney disease.
|
31309036 |
2019 |
Left Ventricular Hypertrophy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study investigates the interrelationship between Klotho protein gene variations, mineral-bone metabolism and left ventricular hypertrophy in patients undergoing chronic haemodialysis programme.
|
31187426 |
2019 |
Left Ventricular Hypertrophy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The A allele of the G-395A Klotho gene polymorphism shows a significantly higher frequency among children with CKD and those with CVD and LVH.
|
29313136 |
2018 |
Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical and experimental studies indicate a possible link between high serum levels of fibroblast growth factor 23 (FGF23), phosphate, and parathyroid hormone (PTH), deficiency of active vitamin D (1,25D) and klotho with the development of pathological cardiac remodeling, i.e., left ventricular hypertrophy and myocardial fibrosis, but a causal link has not been established so far.
|
29977226 |
2018 |
Left Ventricular Hypertrophy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
-Conclusions: Markers of collagen turnover and changes in klotho levels are potential novel pathways associated with regression of LVH in the dialysis population, which will require further prospective validation.
|
29621747 |
2018 |
Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are a lot of evidences that Klotho deficiency correlates with the occurrence and development of coronary artery disease, atherosclerosis, myocardial infarction, and left ventricular hypertrophy.
|
30671457 |
2018 |
Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will discuss the current experimental and clinical evidence regarding FGF23 and Klotho, with a particular focus on their roles in LVH, atherosclerosis, and VC.
|
28294047 |
2018 |
Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, recombinant FGF-23 administration similarly decreased the kidney expression of <i>α</i>-Klotho and induced LVH in mice.
|
28993502 |
2018 |
Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The bone-derived phosphaturic and sodium-conserving hormone fibroblast growth factor-23 (FGF23) and its co-receptor Klotho have been implicated in the development of uremic LVH.
|
28900153 |
2017 |
Left Ventricular Hypertrophy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FGF-23 (Z = 5.03; P < 0.001) and soluble α Klotho (Z = 5.61; P < 0.001) were higher in cirrhotics, and both were related to liver function, independently of serum creatinine FGF-23 levels were higher among alcoholics with diabetes (Z = 2.55; P = 0.011) or hypertension (Z = 2.56; P = 0.01), and increased body fat (ρ = 0.28; P = 0.022 for trunk fat), whereas α Klotho levels were higher in patients with LVH (Z = 2.17; P = 0.03) or atrial fibrillation (Z = 2.34; P = 0.019).
|
28651327 |
2017 |
Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.
|
21985788 |
2011 |